Abstract:As a promising radiotherapy technology, stereotactic body radiotherapy (SBRT) enables precise delivery of high-dose radiation in a short course. The characteristic of SBRT is that a high dose outside the target area decreases rapidly, which can ensure the therapeutic dose of the target area and can also minimize the exposure dose of the organ at risk around the target area when compared with regular radiotherapy. Currently, SBRT has become an effective treatment for early stage NSCLC especially for older patients when they are not suitable for operation. We have read with interest this article by Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar about the optimal dose for SBRT in patients with early NSCLC. Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar investigated a large cohort with over 20,500 patients. They found that 5-year overall survival (OS) rates were 26% for low biologically effective dose (BED) (BED10 < 130 Gy) and 34% for high BED (BED10 ≥ 130 Gy) groups (p = 0.039), suggesting that a BED10 of 130 Gy and above may confer an additional survival benefit. We would like to point out some concerns regarding this article. First, the authors should consider the competitive risk relationship between cancer-caused death and noncancer-caused death, which is highly related to age. In this article, 70% of patients are more than 70 years old. Thus, noncancer-caused death could be the primary reason for the death toll. Second, we wonder whether the age range was well-balanced between the low-BED and high-BED groups, because the authors only divided patients into two groups (age <70 y and age ≥70 y). We believe that the authors should perhaps need to divide the age into more stratifications (such as <70 y, 75–80 y, 80–85 y, >85 y) or consider the age as a continuous variable in propensity-score matching. Recent studies revealed that SBRT, combined with other treatments, was associated with improved survival. Grinnell et al.2Grinnell M. Appiah A.K. Baine M. et al.Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients [e-pub ahead of print]. J Geriatr Oncol.https://doi.org/10.1016/j.jgo.2020.04.014Google Scholar found adjuvant chemotherapy after SBRT was associated with improved OS in patients more than 70 years old with tumors greater than or equal to 4 cm2. SBRT and immune checkpoint inhibition are rapidly growing and effective treatment modalities.3Käsmann L. Eze C. Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death?.Int J Radiation Oncol Biol Phys. 2020; 108: 225-226Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar In the randomized phase 2 study (PEMBRO-RT) trial, compared with pembrolizumab, SBRT followed by pembrolizumab revealed a doubling of the OS (15.9 mo versus 7.6 mo) and objective response rate (36% versus 18%) in advanced NSCLCs.4Theelen W.S.M.E. Peulen H.M.U. Lalezari F. et al.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1276-1282Crossref PubMed Scopus (243) Google Scholar These combinations greatly expand the application range of SBRT. As the population ages, there will be a higher proportion of patients who are suitable for SBRT. Therefore, SBRT is a promising method for future clinical applications.

Optimal Radiotherapy Fractionation Regimens for Early-Stage Non-Small-Cell Lung Cancer

Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma

Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma

Efficiency of moderately hypofractionated radiotherapy in NSCLC cell model

Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC

Understanding the impact of radiotherapy fractionation on overall survival in a large head and neck squamous cell carcinoma dataset: a comprehensive approach combining mechanistic and machine learning models

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.

Reirradiation with Stereotactic Body Radiotherapy for Primary or Secondary Lung Malignancies: Tumor Control Probability and Safety Analyses

Modeling of the resensitization effect on carbon-ion radiotherapy for stage I non-small cell lung cancer

Cost-effectiveness of Stereotactic Body Radiotherapy Versus Conventional Fractionated Radiotherapy for Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer

Promising Stereotactic Body Radiotherapy in NSCLC

PUB114 Dose-Response Relationship for Safety and Efficacy Using Stereotactic Body Radiation Therapy for Centrally-Located Non-Small Cell Lung Cancer

Dosimetry Study of Fourtypes of Radiotherapy Plan Optimization Methods in the Hypofractionated Radiotherapy for Lung Cancer

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer

T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer

Proton Pencil-Beam Scanning Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies: Patterns of Practice Survey and Recommendations for Future Development from NRG Oncology and PTCOG

Hypofractionated Stereotactic Radiation Therapy for Intact Brain Metastases in 5 Daily Fractions: Effect of Dose on Treatment Response

Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity

[Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy]

Comparative analysis of dose calculation algorithms for CyberKnife-based stereotactic radiotherapy in lung cancer